Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. - Wikidata - awgldk - TriplyDB

Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease.

Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease.

http://www.wikidata.org/entity/Q33810241

about

Chemoproteomic Profiling of Bile Acid Interacting Proteins Sasa borealis stem extract attenuates hepatic steatosis in high-fat diet-induced obese rats.Molecular pathways in non-alcoholic fatty liver disease.Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective.SteatoNet: the first integrated human metabolic model with multi-layered regulation to investigate liver-associated pathologies.Fish oil increases atherosclerosis and hepatic steatosis, although decreases serum cholesterol in Wistar rat.Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob/ob mice.FXR and liver carcinogenesis Severe diabetes and leptin resistance cause differential hepatic and renal transporter expression in mice.Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease.Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1.Nuclear receptors reverse McGarry's vicious cycle to insulin resistance.Comparative analysis of temporal and dose-dependent TCDD-elicited gene expression in human, mouse, and rat primary hepatocytes A systems approach implicates nuclear receptor targeting in the Atp7b(-/-) mouse model of Wilson's disease.Dietary carnosic acid suppresses hepatic steatosis formation via regulation of hepatic fatty acid metabolism in high-fat diet-fed mice.Bile acid receptors in non-alcoholic fatty liver disease.Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes.Role of microRNAs in the regulation of drug metabolism and disposition genes in diabetes and liver disease.GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells.O-GlcNAc: A Bittersweet Switch in Liver Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice.Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?Molecular mechanisms of fatty liver in obesity.Molecular basis of alcoholic fatty liver disease: From incidence to treatment.The pharmacological management of NAFLD in children and adolescents.The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Nuclear receptors and nonalcoholic fatty liver disease.Impact of Dietary Fibers on Nutrient Management and Detoxification Organs: Gut, Liver, and Kidneys.The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease.Bioenergetic cues shift FXR splicing towards FXRα2 to modulate hepatic lipolysis and fatty acid metabolism.Microbial Factors in Inflammatory Diseases and Cancers.Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner.On the relationship of anthranilic derivatives structure and the FXR (Farnesoid X receptor) agonist activity.Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease.Ethanol Extract of Pinus koraiensis Leaf Ameliorates Alcoholic Fatty Liver via the Activation of LKB1-AMPK Signaling In Vitro and In Vivo.Effects of Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease in an Obese Rat Model.Causes and mechanisms of adipocyte enlargement and adipose expansion.Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors.

P2860

Q33731122-66FAA09F-C7AD-4331-88EC-E79C692259F3 Q33813669-29EF1A14-187D-4F9C-95E0-21581BE4D208 Q33890230-3D43D724-E785-4C1D-9DFB-2F237D2A8AB8 Q34303001-DFC824AE-6850-4562-8168-BD020C95A373 Q34412650-2DA8FBED-3893-45F9-A230-C9AA139C8F2D Q35513572-F1BEBF2F-7F2E-4DC6-A55A-5CDF1F98E29C Q35544850-514AF7B2-2224-4631-95ED-89F7BCEE8583 Q35998233-FBF6B1B4-C677-487D-9F11-818DBDA385F1 Q36063712-598E5EE2-D0FF-46CE-B1CF-EDE202163F59 Q36156379-87B7BBCE-7078-4520-A316-0EDB590FB90E Q36333338-2C6CA5F8-4554-4FB4-81D4-245AF124AABD Q36379917-96C9D341-6E80-4B30-B23C-D50292BD3A0B Q36626898-33F206AB-70EB-4880-B26C-D68435346503 Q36732028-C55DD873-DD87-4180-B766-20674B8D0AF3 Q36769360-782CD655-E0B3-4717-B9EA-82E83F70D42E Q36964471-10E3FE1D-08FC-4B6E-BB44-4A8F2683791E Q37101805-7D24106D-E574-4284-A3C6-3FCB61CAAE41 Q37586952-270C8CCE-4EB9-49D1-9138-9DA2FE84326F Q37995315-D785E554-1846-4B0A-9140-8B52F93855F4 Q38097092-5CC9264E-AACC-4A30-B908-04BB8A5CF13F Q38303031-FE0F0163-18E8-47E4-BDF6-4467BFC43DE0 Q38310202-89BEA270-B0D0-44AF-A318-F5E29C4AA68C Q38318241-F3F39CB1-2FEE-445F-B8A0-5681509769C0 Q38516786-84F0ABF0-0D64-4159-8C9A-5852AEA265C9 Q38569945-FCAF054A-34B2-466B-B7B9-709D476DD0B8 Q38595071-8EF15640-A032-49E5-B12B-0FF855827A7E Q38643266-60AE837E-48D5-453D-B6D7-1994AC187FEE Q38656970-7F2B673D-CED7-4B6E-BB22-13B7972FC78C Q38768048-2525B901-CE5D-4F32-A165-30D242819CF7 Q39111416-FAC677CF-C0D4-4B1D-A68B-36A5471DE3E4 Q40897334-88D5CD6A-F4A6-4143-9B51-201C219C915B Q41974559-1A7E81B4-7EB5-41D7-8957-A077C34437CE Q41997065-78BEE20F-9FF0-4D58-B6DB-8FBCD59E8ED6 Q42873394-985D0D51-16F7-4EE8-AAF7-EC2E3D732415 Q47297106-12E8F3E6-2FFF-40C4-90D7-6D7A8EE68407 Q47791527-116B7E65-C603-494C-A14E-D87DB9988EFE Q48118035-888FB481-809F-43C7-8059-40AFEEA88C44 Q48346217-7AAECDFA-FCFF-49B1-B74D-6586EF4AAEC1 Q49832016-3A144806-A132-4F1B-945D-EBDE50B59E97 Q50154698-2FEB9F0E-BA16-4F22-8B4F-18B637B0D5B3

P2860

Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease.

http://www.wikidata.org/entity/Q33810241

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effects of nuclear receptor FX ...... alcoholic fatty liver disease.

@ast

Effects of nuclear receptor FX ...... alcoholic fatty liver disease.

@en

type

label

Effects of nuclear receptor FX ...... alcoholic fatty liver disease.

@ast

Effects of nuclear receptor FX ...... alcoholic fatty liver disease.

@en

prefLabel

Effects of nuclear receptor FX ...... alcoholic fatty liver disease.

@ast

Effects of nuclear receptor FX ...... alcoholic fatty liver disease.

@en

P1433

Q33810241-F46D076D-DBB2-4309-AA54-5BFE8BFE4F39

P1476

Q33810241-71B6DC50-E101-4060-8657-93440C4DDD11

P2093

Q33810241-49AFF42D-33E1-491F-AC77-3DD6F3329012

Q33810241-9846B54C-2793-495A-AFCE-7A6A94C3057A

Q33810241-F90470B7-AA2A-44AB-9C08-8A744F66D6C8

P2860

Q33810241-17EEF9AD-13DC-47BB-9231-09E740EE78F5

Q33810241-1A42F2CE-CB38-4714-AB0C-8155DB13E774

Q33810241-31A54533-F272-4925-9958-226B9323D18C

Q33810241-32873AF5-A031-45DF-B62E-140B0782980B

Q33810241-3D239EB8-CEC3-4389-8CD7-D9764978268C

Q33810241-3E069D0A-6B62-48EB-B5B3-4C2862D89783

Q33810241-43D231D7-BD22-47E7-9C82-7534E42D8A10

Q33810241-48A0CB0C-AC69-43C4-AC4B-D4A031FE8EE3

Q33810241-4ED619BB-55D2-4490-B949-33BB6174ADE3

Q33810241-69BEDF23-3491-4366-9A32-711215D0A162

P2888

Q33810241-768C863F-0F0B-4CE1-BBAC-0D2FA8B8B227

P304

Q33810241-9AF7D207-2E68-43BF-BCCA-9C3D32A05876

P31

Q33810241-8BDBC8F6-2C2D-41BC-A1C7-F6E2DBB2F78B

P356

Q33810241-393E90D0-D218-4003-A292-A5EE23659C3C

P433

Q33810241-96FF7AC5-D6BA-4494-83D9-744931EFDFF5

P478

Q33810241-E53CADB0-89FF-4C00-9A75-6C7E537E7054

P577

Q33810241-DF8D62EE-87D1-4574-8F3B-392C06031BCD

P5875

Q33810241-CF20C0AB-9E95-4525-A11A-6782F919C248

P6179

Q33810241-23774442-B22E-4C04-AB91-CE5B24F2F13A

P698

Q33810241-1623D3A2-8CEF-4C57-8438-AB6E88F6018E

P921

Q33810241-01BD5196-036A-4FDE-A23C-A8C04E999D09

P932

Q33810241-7EDF6301-CE7F-4B9E-B514-B787A40F39BF

P356

S12072-010-9202-6

P1433

Hepatology international

P1476

Effects of nuclear receptor FX ...... alcoholic fatty liver disease.

@en

P2093

Hang Sun

http://www.w3.org/2001/XMLSchema#string

Wei Shen

http://www.w3.org/2001/XMLSchema#string

Zhao-Xia Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a nuclear receptor for bile acids

Bile acids: natural ligands for an orphan nuclear receptor

Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations

Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice

Nuclear hormone receptors and gene expression

Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor

SREBP-1c transcription factor and lipid homeostasis: clinical perspective

Identification of a nuclear receptor that is activated by farnesol metabolites

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c

P2888

s12072-010-9202-6

P304

741-748

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12072-010-9202-6

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49803089

http://www.w3.org/2001/XMLSchema#string

P6179

1029407983

http://www.w3.org/2001/XMLSchema#string

P698

21286345

http://www.w3.org/2001/XMLSchema#string

P921

P932

2994619

http://www.w3.org/2001/XMLSchema#string